PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
March 18, 2015 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
October 14, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
June 04, 2014 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
April 17, 2014 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...
Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist
April 03, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...
Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials
March 03, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are...
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
February 24, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
February 19, 2014 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics
December 17, 2013 08:30 ET
|
InvestorIdeas.com
NEW YORK, NY and POINT ROBERTS, WA--(Marketwired - Dec 17, 2013) - Investorideas.com, an investor news and research portal issues an exclusive sector snapshot on the rapidly growing exosome market...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
December 16, 2013 09:15 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...